You are here: Industry Insights > Vectura

News List

Philip Morris Heats Up Race for Vectura With $1.4 Billion Bid firstwordpharma
August 09, 2021
Philip Morris International on Sunday bid £1.65 per share for Vectura Group, after Carlyle on Friday offered £1.50 per share, Bloomberg reported.
Philip Morris agrees to acquire Vectura for $1.45bn pharmaceutical-technology
July 13, 2021
Philip Morris International (PMI) has made an offer to acquire a contract development and manufacturing organisation (CDMO), Vectura Group, for approximately $1.45bn (£1.045bn) to boost its product pipeline development expertise in inhaled treatments.
Vectura to provide preclinical support for Incannex's inhaled brain injury treatment cphi-online
June 24, 2021
IHL-216A may make sports safer and reduce the morbidity and mortality rates of people suffering serious head traumas
Vectura, Incannex Enter Preclinical Services Agreement contractpharma
June 23, 2021
Vectura to provide development services for IHL-216A, Incannex’s inhaled drug product for the treatment of traumatic brain injury.
Carlyle Group to acquire pharma company Vectura for $1.36bn pharmaceutical-technology
May 28, 2021
Carlyle Group has entered an agreement, through which its affiliate Murano Bidco will acquire 100% shares of pharmaceutical firm Vectura Group in a deal worth $1.36bn (£958m).
Vectura, Inspira Partner to Develop Inhaled COVID Treatment contractpharma
May 08, 2021
Vectura Group plc, an inhalation CDMO, and Inspira Pharmaceuticals, a UK-based company focused on developing therapies for respiratory and infectious diseases, entered an agreement to develop an inhaled formulation of Inspira’s lead drug candidate ...
Vectura, Kinaset Therapeutics set to develop inhaled asthma drug pharmatimes
December 03, 2020
UK-based Vectura Group has signed an agreement with Kinaset Therapeutics to develop and commercialise a preclinical inhaled pan-JAK inhibitor for the treatment of severe asthma.
Vectura, Kinaset Partner to Develop Asthma Treatment contractpharma
December 01, 2020
Licenses VR588 to Kinaset, Vectura will provide formulation development services to support Phase I studies and ultimately commercialization.
Vectura and Monash University Support Development of Inhaled Oxytocin contractpharma
September 15, 2020
Vectura Group plc has signed an agreement with Monash University’s Institute of Pharmaceutical Sciences (MIPS), to develop inhaled oxytocin delivered via a dry powder inhaler to prevent postpartum hemorrhage (PPH) in childbirth.
Vectura Earns $5M Novartis Milestone for Enerzair Breezhaler contractpharma
July 08, 2020
Enerzair Breezhaler uses Vectura’s formulation IP, and is a first-in-class fixed-dose combination maintenance treatment for uncontrolled asthma.

Previous page 1 2 Next page